A New Approach to Examine Cell-Antibody Avidity with Surface Plasmon Resonance Imaging.

Richard B M Schasfoort, Elise van Doorn, Jos van Weperen, Anouk Mentink, Ruchi Bansal

Abstract read

In one paragraph

Article in Biosensors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Richard B M SchasfoortDepartment of Bioengineering Technologies, Technical Medical Centre, Faculty of Science and Technology, University of Twente, P.O. Box 217, 7500 AE Enschede, The Netherlands.ORCID 0000-0003-1601-3853

Elise van DoornDepartment of Bioengineering Technologies, Technical Medical Centre, Faculty of Science and Technology, University of Twente, P.O. Box 217, 7500 AE Enschede, The Netherlands.

Jos van WeperenVysens B.V., Fl. Hazemeijerstraat 800/A04, 7555 RJ Hengelo, The Netherlands.

Anouk MentinkDepartment of Bioengineering Technologies, Technical Medical Centre, Faculty of Science and Technology, University of Twente, P.O. Box 217, 7500 AE Enschede, The Netherlands.

Ruchi BansalDepartment of Bioengineering Technologies, Technical Medical Centre, Faculty of Science and Technology, University of Twente, P.O. Box 217, 7500 AE Enschede, The Netherlands.ORCID 0000-0003-2470-5876

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In recent years, avidity has emerged as a critical parameter in antibody design, yet most current analytical instruments are limited to measuring affinity alone. This study aims to evaluate the capabilities and advantages of a novel surface plasmon resonance imaging instrument, CellVysion, designed to quantify cell-antibody avidity using a continuous antibody density gradient. A key feature of this approach is the identification of a "tipping point"-the specific ligand density, measured in µRIUs, at which cells remain bound to the sensor surface under defined shear flow conditions. In this paper, we present the technical principles and application of this method, demonstrating how avidity can be quantitatively assessed across different antibody-cell line combinations.

Indexed as

AntibodiesAntibody AffinitySurface Plasmon ResonanceAnimalsHumansAntibodiesaviditybiosensorcell ligand interactionligand density gradientsurface plasmon resonance imagingtipping point

Identifiers

PMID41002299

DOI10.3390/bios15090559

PMCPMC12467693

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.